background: In spite of tremendous efforts by a number of groups, the search for single nucleotide polymorphisms (SNPs) strongly associated with male factor infertility by means of gene re-sequencing studies has yielded few likely candidates. A recent pilot, genome-wide SNP association study (GWAS) identified a list of SNPs associated with oligozoospermia and azoospermia. This is an expanded follow-up study of the SNPs identified by the GWAS as well as other SNPs from previously published gene re-sequencing studies.
Introduction
Infertility affects approximately one in seven couples worldwide resulting in significant financial and emotional costs, and male factor infertility accounts for about half of all infertility cases. Despite its prevalence, infertility research has received much less attention than most common, complex diseases.
Common known genetic causes of male infertility include Klinefelter's syndrome and Y chromosome microdeletions, both resulting in severe oligozoospermia or azoospermia, and cystic fibrosis transmembrane conductance regulator mutations, which result in congenital bilateral absence of vas deferens leading to obstructive azoospermia (Nuti and Krausz, 2008) . Taken together, known genetic causes of male infertility account for less than one-third of all male factor infertility cases leaving a large proportion of cases classified as idiopathic (Dohle et al., 2002) .
Due to the limited attention given to male infertility research and a concomitant lack of substantial research funding, the majority of research has focused on targeted gene re-sequencing studies in search of genetic risk factors. Although several single nucleotide polymorphisms (SNPs) associated with various classes of male infertility have been reported, for the majority, associations are weak and replication studies often fail to validate initial findings. To date only a single pilot genome-wide SNP association study (GWAS) has been performed for idiopathic male infertility (Aston and Carrell, 2009) . In this pilot study from our laboratory, no single SNP reached the level of genome-wide significance after adjusting for multiple comparisons (Bonferroni adjustment), however, we did find 20 SNPs with a raw P-value for association ,1 × 10 25 and an estimated false discovery rate of ,0.3 (Aston and Carrell, 2009) . Although the pilot GWAS represented an important first step in the search for genetic variants associated with severe oligozoospermia and non-obstructive azoospermia on a genome-wide scale, the study evaluated a limited number of samples and the associations detected were marginal for a GWAS. In the initial study, we stressed the need for follow-up studies with increased sample size to evaluate the preliminary results. For the present study, we have evaluated a larger population of azoospermic and oligozoospermic men utilizing BeadXpressw (Illumina Inc., San Diego, CA, USA) technology as a cost effective medium-throughput assay for a targeted genotyping follow-up of the findings of the initial study. Additionally, we have simultaneously genotyped this population of men for SNPs identified in prior gene re-sequencing studies and target genes of spermatogenesis. We evaluated the data for the follow-up study separately, and after combining with the data from the initial GWAS.
Materials and Methods

Study samples
Details of patient and control selection for the pilot microarray study were published previously (Aston and Carrell, 2009) . Caucasian individuals of central European descent, including normospermic controls (n ¼ 80) with .20 million sperm/ml, severe oligozoospermic individuals (n ¼ 50) with ,5 million sperm/ml and non-obstructive azoospermic individuals (n ¼ 33) with no detectable sperm in the ejaculate following evaluation of the centrifuged pellet and with no other known etiology, were included in the study.
Patient and control samples used in the follow-up targeted genotyping study included individuals of European decent-primarily of Mediterranean origin. Infertile patients included in the study were seeking a complete andrological diagnostic work-up for couple infertility. All infertile patients were defined as 'idiopathic' and selected on the basis of a comprehensive andrological examination including medical history and physical examination, semen analysis, scrotal ultrasound, hormone analysis, karyotype and Y chromosome microdeletion screening. Patients with mono or bilateral cryptorchidism, varicocele, previous testis trauma, obstructive azoospermia, recurrent infections, iatrogenic infertility, hypogonadotrophic hypogonadism, karyotype anomalies or Y chromosome microdeletions including gr/gr deletions were excluded.
In all, 158 normospermic controls (.20 million sperm/ml), 141 severe oligozoospermic individuals (,5 million sperm/ml) and 80 nonobstructive azoospermic individuals were included in the follow-up study. In addition, 63 moderately oligozoospermic individuals (5-10 million sperm/ml) were analyzed, and associations with all oligozoospermic men are reported separately.
DNA extraction
DNA was extracted from whole blood using the Gentra Puregene Blood Kit (Qiagen Inc., Valencia, CA, USA) according to manufacturer's recommendations. Briefly, red blood cells were lysed, and white cells pelleted followed by white cell lysis. Protein precipitation solution was added and lysis solution spun to remove proteins. DNA was then precipitated using 100% isopropanol, washed and re-suspended in Tris-EDTA. DNA concentration was assessed using the NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) and subsequently adjusted to 50 ng/ml. Purified DNA was stored at 2808C prior to use.
Follow-up targeted genotyping assay design
A total of 84 SNPs were evaluated as a follow-up to the initial GWAS, microarray pilot study. Three different groups of SNPs were selected for follow-up based on associations detected in the microarray phase of the study. Since the pilot study was limited in its power to detect by the relatively small sample size, we used a lower threshold P-value for selection of SNPs for the follow-up study. This was done to improve our chances of validating true associations in spite of the lack of power. SNPs with a P-value for association ,5 × 10 25 (n ¼ 32), SNPs located within 10 kb of genes with known fertility function based on phenotype in mouse gene knockout models (Bult et al., 2008; Matzuk and Lamb, 2008 ) with a P-value for association ,5 × 10 23 (n ¼ 20), and non-synonymous SNPs with a P-value for association ,5 × 10 23 (n ¼ 32) were selected for follow-up with additional samples (Table I) . In addition to SNPs with significant associations based on the microarray pilot study, 21 SNPs associated with spermatogenic defects reported in literature (Table II) were evaluated as well as 67 non-synonymous SNPs located within genes important in spermatogenesis (Table I) . SNPs targeted for genotyping based on previous publications were located in AHRR, BRCA2, ER beta, ERCC1, ESR1, FASLG FHL5, FKBP6, IL1B, KIT, MS, MTHFR, MTRR, PRM1, TSSK4, UBE2B and YBX2 (Table II) . Non-synonymous SNPs in spermatogenesis genes included SNPs in AR,  BRDT, CAMK4, CREM, DDX25, DMC1, FHL5, JMJD1A, KIF17, MSH4,  MSH5, PRM1, PRM2, REC8, SMC1B, SPATA22, SPO11, STRA8, SYCP1,  SYCP2, TEX11, TEX14, TEX15, TNP1, TNP2, USP26 and YBX2  (Table III) . In all, the final BeadXpress assay targeted 172 SNPs (Table I) .
Follow-up genotyping
Genotyping was performed on purified DNA samples using the Illumina BeadXpressw Assay (Illumina Inc., San Diego, CA, USA) according to manufacturer's recommendations. Briefly, DNA was purified from peripheral blood lymphocytes as described above. Approximately 500 ng of purified DNA at a concentration of 50 ng/ml was delivered to the University of Utah Genomics Core Facility (Salt Lake City, UT, USA) for genotyping where it was prepared by several activation and ligation steps followed by universal PCR and finally hybridization to SNP-specific genotyping beads. Following hybridization and wash steps, reaction plates were scanned, the raw data were normalized across samples and genotype calls were made using BeadStudio Softwarew (Illumina Inc).
Genotype and haplogroup association analysis
Associations were tested using GoldenHelix w SVS7 analysis software (Bozeman, MT, USA). Initial data cleanup was performed to remove poorly performing probes and samples from analysis. Probes with a call rate ,0.95 and probes with significant deviations from Hardy-Weinberg equilibrium (HWE) within controls of P , 0.001 were removed prior to association analysis. Samples with a call rate of ,0.85 were also removed from analysis.
SNP association analysis was performed applying allelic, additive, dominant and recessive models to the data. Allelic association was performed on autosomal probes, whereas all probes were analyzed using the other models. Primary comparisons made for association testing included azoospermic versus normospermic (AvN), severe oligozoospermic versus normospermic (OvN) and azoospermic and severe oligozoospermic combined versus normospermic (A+OvN 
Continued
SNPs associated with oligozoospermia and azoospermia samples were included in the initial analysis to match the phenotypes included in the pilot GWAS. In addition to the primary comparisons, an additional aim of the study was to evaluate the question of whether azoospermia or severe oligozoospermia result from SNPs specific to each individual infertility phenotype, or whether SNPs common to both of these groups result in differing severities of spermatogenic defects. In order to address this question, oligozoospermic and normospermic data combined served as the control group and were compared with azoospermic individuals (A versus O+N), and conversely azoospermic and normospermic groups were combined and compared with oligozoospermic individuals (O versus A+N). A P-value of ,0.05 was considered significant.
In addition to a univariate analysis to evaluate the association between single SNPs and spermatogenic defects, haplogroup association was also performed to evaluate whether a specific haplogroup was more powerful in predicting a phenotype than a single SNP. For this analysis, a moving window of 100 kb was used to define haplogroups. The expectedmaximization (EM) algorithm with 50 iterations and a convergence tolerance of 0.0001 was employed for haplotype estimation (Excoffier and Slatkin, 1995) . A P-value of ,0.05 for association was considered significant.
As haplogroup association assumes linkage between SNPs, additional analysis was performed to determine whether azoospermic and oligozoospermic samples carried more total independent risk SNPs compared with controls based on associations detected by univariate analysis. Differences in total numbers of risk SNPs between groups were evaluated using the un-paired Student's t-test.
Oligozoospermic sperm count and genotype analysis
For SNPs found to be associated specifically with oligozoospermia, further analysis was performed to determine whether an association between the 'risk allele' and sperm concentration existed. To perform this analysis, samples were grouped based on genotype for each associated SNP, and sperm concentrations were compared between groups.
Results
Sample quality
There were 158 normospermic controls, 63 moderately oligozoospermic samples, 141 severe oligozoospermic samples and 80 nonobstructed azoospermic samples analyzed by BeadXpressw assay. Poorly performing samples with genotyping call rates of ,0.85 (n ¼ 2 severe oligozoospermic samples) were removed from association testing leaving 158 controls, 63 moderately oligozoospermic samples, 139 severe oligozoospermic samples and 80 azoospermic samples. Five samples were run in duplicate across plates, and average SNP concordance between samples was 99% across all markers.
Genotype associations for microarray follow-up SNPs
Association data from the pilot microarray study were recently published (Aston and Carrell, 2009) . A total of 84 markers were designed to target SNPs as a follow-up to results obtained following a pilot genome-wide association study. Probes with a call rate ,0.95 (n ¼ 13), and probes with significant deviations from HWE within controls of P , 0.001 (n ¼ 1), were removed prior to association analysis, leaving 70 markers for analysis.
Of the 70 SNPs evaluated for association in the follow-up study based on associations detected in the pilot study, four SNPs displayed improved associations upon combining genotypes from the two projects (Table IV) .
Genotype associations for published and spermatogenesis gene SNPs
Additionally, 67 non-synonymous SNPs in genes important in spermatogenesis, and 21 SNPs with published associations with spermatogenic defects for a total of 88 SNPs were genotyped. Because 11 markers had a call rate of ,0.95, they were removed, leaving 77 markers included in the analysis.
Of the 77 SNPs evaluated for association based on previously published associations or SNP function, 31 displayed a minor allele frequency of 0 in our study population, so those SNPs were not included in association analysis. The remaining 46 SNPs were tested for association with azoospermia or oligozoospermia, and five SNPs were found to have significant associations at P , 0.05 (Table IV) SNPs are listed in order of significance based on P-value in the targeted genotyping study. Design category: selection of SNPs for study was based on previous microarray results (M), SNPs with previously published associations with infertility (P) or non-synonymous SNPs in spermatogenesis genes (S Interestingly, only one of these five significant SNPs was selected based on previously published data. In other words, only one SNP from previous re-sequencing studies showed significant association in this study.
Effect of inclusion of moderate oligozoospermic samples on SNP associations
When moderately oligozoospermic samples were included along with the severe oligozoospermic samples, associations for six SNPs improved, whereas associations for eight SNPs declined (Table V) .
SNP associations with inclusion of alternative comparisons
When A versus O+N and O versus A+N comparisons were made, associations improved for four SNPs that were significant using the conventional A versus N, O versus N and A+O versus N comparisons. In addition, five more SNPs reached significance with the added statistical power derived from a larger number of control samples (Table V) .
Haplogroup associations
A total of seven haplogroups were found to display significant associations with infertile phenotypes at P , 0.05 when A versus N, O versus N and A+O versus N comparisons were made excluding moderate oligozoospermia (Table VI) . Including the comparisons A versus O+N and O versus A+N in the association testing increased the number of significant associations to nine. Inclusion of moderate oligozoospermic patients in the oligozoospermia group resulted in improved associations for only one haplogroup and reduced associations for three haplogroups (Table VII) . Analysis of the number of risk SNPs per sample revealed that, as expected, multiple risk SNPs were present at a higher frequency in cases compared with controls (P , 0.05).
Oligozoospermic sperm count and genotype analysis
Comparison of mean sperm counts in oligozoospermic samples displaying a 'risk allele' versus those without for the SNPs most significantly associated with oligozoospermia revealed no difference in sperm count between groups for any of the SNPs analyzed.
Discussion
The data presented here represents the most comprehensive SNP study for male infertility performed to date. In all, genotype data for 147 SNPs across several hundred samples is reported. Of the 147 SNPs evaluated, we report significant associations for a total of 14 SNPs at P , 0.05 when all samples and comparisons were included (Table V) . It should be noted that the P-values for association reported here have not been corrected for multiple comparisons. With 147 independent tests, a P-value of 0.0003 would be required to achieve a Bonferroni-adjusted P-value of ,0.05. The most significant association found in this study is for rs5911500. This is an intergenic SNP located on the X chromosome 200 kb from solute carrier family 6, member 14 (SLC6A14). On the basis of the intergenic location of rs5911500, if the SNP is a functional variant responsible for the oligozoospermia phenotype, it is most likely involved in a regulatory capacity. Indeed, many SNPs associated with a variety of complex diseases are located in gene deserts, providing further evidence that uncharacterized functional elements are located in those regions (Easton and Eeles, 2008; Mathew, 2008) .
Three SNPs located within receptor protein genes were significantly associated with azoospermia or oligozoospermia. The SNP rs2059807, associated with oligozoospermia, is an intronic SNP located on chromosome 19 of the insulin receptor gene (INSR). Rs11204546 is a non-synonymous SNP located in the olfactory receptor, family 2, subfamily W, member 3 gene (OR2W3) on chromosome 1. This polymorphism is associated with both azoospermia and severe oligozoospermia and results in a conservative Methionine to Valine amino acid change. Rs10246939 is another non-synonymous SNP located in the taste receptor, type 2, member 38 gene (TAS2R38) on chromosome 7 and is associated specifically with azoospermia. This SNP also results in a conservative amino acid change of Isoleucine to Valine. Although none of these receptors have been directly implicated in spermatogenesis, receptor proteins of a variety of classes have been shown to be present in the testes (Oonk and Grootegoed, 1987; Thomas et al., 1996) .
SNPs with significant associations with spermatogenic failure were also found in testis expressed 15 (TEX15), fas ligand (FASLG), bromodomain, testis-specific (BRDT) and lysine-specific demethylase 3A (JMJD1A). The associated SNPs in TEX15, BRDT and JMJD1A all result in conservative amino acid substitutions, and the SNP in FASLG is a non-coding SNP located in the promoter region of the gene. Each of these genes is specifically involved in spermatogenesis.
TEX15 was recently shown to be necessary for spermatogenesis but not oogenesis. Knockout of the gene in mice resulted in early meiotic arrest in males resulting in a complete lack of germ cells . Further analysis revealed TEX15 is required for normal chromosomal synapsis and that the protein is likely involved in the loading of DNA repair machinery at the point of DNA doublestrand breaks, with gene loss resulting in the meiotic arrest as observed in Tex15-deficient male mice . Although the associated SNPs result in conservative amino acid changes to the protein, a direct link to impaired spermatogenesis in unclear.
The SNP rs763110 in the promoter region of FASLG, a gene involved in germ cell apoptosis induction, was recently shown by meta-analysis to be associated with cancer susceptibility ). This SNP was selected for study based on a recent report of its association with male infertility . In this report, azoospermic and severe oligozoospermic men together more frequently carried the risk genotype than controls . In contrast, we found the SNP to associate with severe oligozoospermia, with no apparent association with azoospermia.
The other two SNPs with significant associations with spermatogenic failure both reside in genes involved in chromatin remodeling. The SNP rs3088232, located in the gene BRDT is associated with severe oligozoospermia in our study. BRDT is a testis-specific protein that interacts with acetylated lysine residues of histones and other proteins (Pivot-Pajot et al., 2003) . Hyperacetylation of histones occurs in male germ cells prior to histone-to-prtotamine replacement. SNPs are listed in order of significance based on P-value in the targeted genotyping study. Design category: selection of SNPs for study was based on previous microarray results (M), SNPs with previously published associations with infertility (P) or non-synonymous SNPs in spermatogenesis genes (S). Test: describes the comparison made for association testing as well as the genetic model applied for association testing. A, azoospermic; SO, severe oligozoospermic; O, oligozoospermic and severe oligozoospermic combined; N, normospermic; AvN, azoospermic versus normospermic; OvN, severe oligozoospermic versus normospermic, A+OvN, azoospermic + oligozoospermic versus normospermic; AvO+N, azoospermic versus oligozoospermic + normospermic; OvA+N, oligospermic versus azoospermic + normospermic; add, additive; all, allelic; dom, dominant; rec, recessive; *, denotes SNPs presented in Table IV ; NA, SNPs not selected for follow-up based on initial microarray results; D, minor allele; d, major allele.
It was recently reported that BRDT binds specifically to histone H4 tails with at least two acetylation marks (Moriniere et al., 2009) . The importance of this protein in spermatogenesis makes it an intriguing candidate for disruption of spermatogenesis. JMJD1A is a histone demethylase that specifically demethylates mono-and di-methylated histone H3 lysine 9. Knockout of Jmjd1a in mice results in reduced testis weight and severe oligozoospermia resulting in infertility (Liu et al., 2010) . It was also found that Jmjd1a knockout resulted in reduced expression of a number of genes important in chromatin remodeling and spermatid elongation (Liu et al., 2010) . As with the other SNPs identified in this study, the functional significance of rs34605051 is not yet known.
As with the majority of associations reported for other GWAS, the involvement of the associated SNPs identified in this study is not immediately clear. The variants identified may not be the actual functional variants, but may be in linkage disequilibrium with the functional variant, as has been determined for the majority of SNPs identified by GWAS (Lettre and Rioux, 2008) . Alternatively, the SNPs identified may affect uncharacterized functional elements within the genome.
In a few cases, haplogroup analysis detected significant associations in genes that were not found when evaluating individual SNPs such as haplogroups in paired box 8 (PAX8) and transition protein 2 (TNP2), however, in most cases no statistical power was gained by evaluating haplogroups as compared with individual SNPs. Although our data indicate that cases were significantly more likely than controls to contain multiple independent risk SNPs, much larger studies will be necessary to accurately characterize the combined effects of multiple independent loci on spermatogenic defects.
In an effort to better characterize the genetic basis for different categories of spermatogenic failure, we performed a number of different comparisons for association testing. In the majority of published male infertility SNP association studies the primary comparison Design category: selection of SNPs for study was based on previous microarray results (M), SNPs with previously published associations with infertility (P) or non-synonymous SNPs in spermatogenesis genes (S). Test: describes the comparison made for association testing as well as the genetic model applied for association testing. A, azoospermic; SO, severe oligozoospermic; O, oligozoospermic and severe oligozoospermic combined; N, normospermic; AvN, azoospermic versus normospermic; OvN, oligozoospermic versus normospermic, A+OvN, azoospermic + oligozoospermic versus normospermic; AvO+N, azoospermic versus oligozoospermic + normospermic; OvA+N, oligospermic versus azoospermic + normospermic; *, denotes haplogroups presented in Table VI. is normospermic or known fertile controls compared with infertile men. The infertile group sometimes includes only non-obstructive azoospermic men or only severely oligozoospermic men, but often azoospermic and oligozoospermic groups are combined. In combining azoospermic and oligozoospermic samples for association testing, the assumption is that the same SNPs contribute to both pathologies. We performed these same comparisons (A versus N, O versus N and A+O versus N) , however, we also evaluated the strength of associations with alternate comparisons (A versus O+N and O versus A+N) . In doing so, we test the assumption that azoospermia and oligozoospermia are disorders with completely separate genetic backgrounds. There is not a compelling amount of evidence to support or refute either of these assumptions, so we report here the significant associations for all of the comparisons made.
A striking result of the current study is the failure of this study to validate essentially all of the previously published SNPs associated with azoospermia or oligozoospermia. Due to limitations of the assay, we were not able to design probes to genotype all of the previously published male infertility SNPs, however, we did perform association testing on 17 previously reported SNPs and found a significant association for only one of those SNPs in our study group. In addition, we performed follow-up association testing for 70 SNPs with strong or marginal associations with azoospermia or oligozoospermia based on our pilot microarray study, and of those SNPs, associations were strengthened for only four.
There are a number of possible reasons for this low rate of validation. Our pilot and follow-up studies both included Caucasians of European decent; however, many of the previously published re-sequencing studies included men of other ethnicities (Table II) . SNP and haplotype frequencies vary widely between ethnic groups. It is, unfortunately, not uncommon for associations reported in one study to fail validation in subsequent studies as a result of insufficient study power, genetic homogeneity between or within studies, or because the initially reported association was spurious (Krausz and Giachini, 2007; Liu et al., 2008) . This again emphasizes the need for rigorous follow-up of reported associations in new patient groups and by means of meta-analyses to achieve additional power when possible (Tuttelmann et al., 2007; Nuti and Krausz, 2008) .
On the basis of these findings, it is likely that male factor infertility is similar in nature to the majority of complex diseases studied to date in that the disease is multigenic and no single SNP is responsible for an appreciable proportion of male factor infertility cases . It seems unlikely that a few SNPs of moderate or large effect are responsible for spermatogenic failure, rather that a large number of rare variants of small effect are responsible, as has been proposed for other complex diseases . Given the wide phenotypic spectrum of male infertility or even non-obstructive azoospermia, it is not surprising that SNPs with strong effect have not been identified. In order to detect real associations for such small effect SNPs, much larger genome-wide studies will be necessary.
To date, genome-wide studies have successfully identified hundreds of genetic variants associated with over 80 different diseases or traits . Mounting evidence based on larger and larger genome-wide studies suggests genotypes for tens or even hundreds of thousands of cases and controls will be required to capture an appreciable proportion of the loci responsible for the heritable component of many common complex diseases (Panoutsopoulou and Zeggini, 2009) . For example, the genetic component of type 2 diabetes (T2D) has been studied extensively over the past few decades. Early gene re-sequencing efforts and genomewide linkage scans successfully identified four important loci associated with T2D over a span of almost 30 years (McCarthy and Zeggini, 2009) . In contrast, the first genome-wide SNP association study of T2D was published in 2007 (Sladek et al., 2007) , and in ,2 years a total of 15 new risk variants have been identified (McCarthy and Zeggini, 2009) .
Although this illustrates the incredible power to identify risk alleles by genome-wide genotyping, a total of six studies cumulatively genotyping over 7000 cases and 13 000 controls were employed (McCarthy and Zeggini, 2009) . Even with the large effort made to understand the genetic component of T2D, the variants identified to date still only account for about 6% of T2D heritability .
Similar results have been obtained for other complex diseases including neurological disorders (Simon-Sanchez and Singleton, 2008; Bertram and Tanzi, 2009) , autoimmune diseases (Lettre and Rioux, 2008; Graham et al., 2009) , cardiovascular disease (Arking and Chakravarti, 2009 ) and a number of different cancers (Savas and Liu, 2009) following multiple large genome-wide studies.
Although these data represent a promising and potentially important group of associations, clearly much larger studies will be necessary to validate these findings and identify new functional variants associated with male infertility. It remains to be seen whether studies evaluating hundreds or a few thousand infertile men will be sufficient to identify risk variants with confidence or whether studies similar in magnitude to the previously discussed diseases will be required, but it is clear that studies need to be expanded significantly if we want to obtain answers. In addition structural variants such as duplications or deletions in the genome have been found to be important risk factors in a number of complex diseases (Frazer et al., 2009; Wain et al., 2009 ). In the case of male infertility, gr/ gr deletion of the Y chromosome (which removes half of the AZFc genes) has been confirmed as a significant risk factor for impaired spermatogenesis (Repping et al., 2003; Giachini et al., 2008; Visser et al., 2009) . Other types of variation may also prove to be important in some cases of male factor infertility and should be evaluated in future studies.
In summary, this is the first follow-up study of a small, pilot genome-wide association study of azoospermia and oligozoospermia. We have further evaluated the SNPs identified in the GWAS, along with SNPs identified from re-sequencing studies and nonsynonymous SNPs from spermatogenesis genes, in Caucasian men of European descent and have identified several SNPs of potential relevance to oligozoospermia and azoospermia. Nevertheless, the study also highlights the need for future large-scale genome-wide association studies with increased statistical power, the need for structural variation studies to identify relevant copy number variations, and the need for genome sequencing of individuals to identify rare variants that are likely to be responsible for a significant proportion of spermatogenic defects. Such studies are becoming technologically practical, but will require profound improvements in collaboration and funding.
